Product Images Clopidogrel Bisulfate

This is a figure showing the exposure to Clopidogrel Aotive Metabolite after taking multiple doses of Clopidogrel alone or with Proton Pump Inhibitors (PPis). The figure includes information on the effect of co-administered PPI on the active metabolite AUC, with mean and 90% confidence interval. It also shows changes relative to clopidogrel administered alone.*

The figure 2 shows the comparison of cardiovascular death, myocardial infarction, and stroke in the CURE study between placebo plus aspirin and clopidogrel with aspirin. The cumulative event rate is presented in percentage for up to 12 months of follow up. Other standard therapies were also used as appropriate. The data suggests that the combination of clopidogrel and aspirin is effective in reducing the incidence of cardiovascular death, myocardial infarction, and stroke.*

The text appears to be a table showing hazard ratio for different subgroups of patients based on their baseline characteristics and on-study concomitant medications/interventions for the CURE study. The table provides data on the number of patients in each subgroup, the percentage of patients in each treatment group (Clopidogrel and Placebo), and whether Clopidogrel or Placebo treatment had a favorable outcome, i.e., a lower hazard ratio. The table also includes hazard ratios with 95% confidence intervals for each subgroup.*

This appears to be a comparison of the death rates between a placebo and Clopidogrel in a medical study conducted over 28 days. The placebo had 1845 deaths (8.1%) while Clopidogrel had 1726 deaths (7.5%). The proportional risk reduction was 7% before reduction (p=0.03). The data is plotted against the number of days since randomization, up to 28 days.*

This is a statistical report of two different treatments for preventing re-infarction and death in patients. The first treatment is called Placeho and the second is Clopidogrel. The report shares the percentage of patients that experienced events (related to the treatment) with each treatment. Among the patients receiving Clopidogrel, there was a proportional risk of death with a reduction in re-infarction (p=0.002). There is also a graph showing the number of days since randomization up to 28 days.*

This text seems to be a table with information about a medical study. It includes data on subgroup N, gender, age, hours since onset, blood pressure, heart rate, and whether fibrinolytic agent was given or not. It also shows the number of people included in the overall study and the CTis 95% for the overall row only. There is also information about the use of Clopidogrel and the Placebo percentage as well as the Odds Ratio. However, without further context, it is difficult to provide more specific information.*

This appears to be a chart or graph displaying the cumulative event rate (in percentage) for fatal or non-fatal vascular events observed over a period of 24 months of follow-up. The chart compares the event rates for two different treatments - Aspirin and Clopidogrel. The variables "n", "@", and "&" do not seem to provide any additional information and may have been misread by the .*

This is a table containing information about the results of a study comparing the effectiveness of Clopidogrel and Aspirin for patients with different qualifying conditions. The qualifying conditions mentioned are stroke and PAD, and the table shows the number of patients in each group, the percentage of patients taking Clopidogrel and Aspirin, and which treatment is favored. The table also includes an overall summary of the results for all qualifying conditions. The last row shows the year of the study and the hazard ratio.*

This is a description of a medication: Clopidogrel 75mg tablet that has been packaged by Eryant Rench Bunbank. It comes in a container that meets the USP standards and it is recommended to be stored at a temperature range of 20°-25°C (68°-77°F). The medication comes in a pink round shape and is meant to be kept in a light-resistant container. The medication is similar to Plavix 75mg tablet and the package was made by SeleGen Pharmaceutiab. There is a total of 90 tablets in the container and it has an expiration date of MMYY 5. The NDC number of the medication is 7133512321 047281132193.*